A new boost for malaria vaccines

Trends in Parasitology

Volumn 20, Issue 4, 2004, Pages 157-160

  Pouniotis, Dodie S ^a   Proudfoot, Owen ^a   Minigo, Gabriela ^a   Hanley, Jennifer C ^a   Plebanski, Magdalena ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALARIA; REVIEW; VACCINATION; VIRUS STRAIN;

ANIMALIA; PLASMODIUM FALCIPARUM; VACCINIA VIRUS;

EID: 1942537078     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2004.01.013     Document Type: Short Survey

References (25)

1. McConkey S.J., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9:2003;729-735.
2. Plebanski M., et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur. J. Immunol. 28:1998;4345-4355.
3. Schneider J., et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine. 19:2001;4595-4602.
4. Doolan D.L., Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165:2000;1453-1462.
5. Plebanski M., et al. Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J. Clin. Invest. 110:2002;295-301.
6. Hoffman S.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185:2002;1155-1164.
7. Herrington D., et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am. J. Trop. Med. Hyg. 45:1991;539-547.
8. Mellouk S., et al. Protection against malaria induced by irradiated sporozoites. Lancet. 335:1990;721.
9. Stoute J.A., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178:1998;1139-1144.
10. Pinder M., et al. Cellular immunity induced by the recombinant P. falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Cell. Exp. Immunol. 135:2004;286-293.
11. Bojang K.A., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 358:2001;1927-1934.
12. Gilbert S.C., et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science. 279:1998;1173-1177.
13. Plebanski M., et al. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity. 10:1999;651-660.
14. Plebanski M., et al. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nat. Med. 5:1999;565-571.
15. Plebanski M., et al. Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein. Parasitology. 115:(Suppl):1997;S55-S66.
16. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today. 21:2000;163-165.
17. Schneider J., et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170:1999;29-38.
18. Apostolopoulos V., Plebanski M. The evolution of DNA vaccines. Curr. Opin. Mol. Ther. 2:2000;441-447.
19. Wang R., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
20. Ockenhouse C.F., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177:1998;1664-1673.
21. Flanagan K.L., et al. Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am. J. Trop. Med. Hyg. 68:2003;421-430.
22. Roy M.J., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine. 19:2000;764-778.
23. Degano P., et al. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine. 18:1999;623-632.
24. Gilbert S.C., et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 20:2002;1039-1045.
25. Rogers W.O., et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect. Immun. 69:2001;5565-5572.